Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Pascual

Showing results (91-100 of 112) with videos related to

Pageof 12
Sort By:
Breast Cancer Research : BCR|May 1, 2025
Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancerIñaki Comino-Méndez, Jesús Velasco-Suelto, Javier Pascual, et al.
JCO Global Oncology|March 21, 2024
Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data StudyNuria Ribelles, Javier Pascual, Laura Galvez-Carvajal, et al.
Plos One|May 29, 2015
Identification of the Lipodepsipeptide MDN-0066, a Novel Inhibitor of VHL/HIF Pathway Produced by a New Pseudomonas SpeciesBastien Cautain, Nuria de Pedro, Christian Schulz, et al.
Breast (Edinburgh, Scotland)|July 14, 2026
The landscape of clonal hematopoiesis of indeterminate potential in long-term breast cancer survivorsLaura Gálvez-Carvajal, Iñaki Comino-Méndez, Esperanza López-López, et al.
Frontiers in Oncology|December 3, 2025
Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapyAna Godoy-Ortíz, Gonzalo Lendínez-Sánchez, Manuel Zalabardo, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 3, 2024
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancerSara Santana-Hernández, Jesús Suarez-Olmos, Sonia Servitja, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2025
The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH TrialIseult M Browne, Javier Pascual, Rosalind J Cutts, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 25, 2023
Comparative study of droplet-digital PCR and absolute Q digital PCR for ctDNA detection in early-stage breast cancer patientsVictoria Sánchez-Martín, Esperanza López-López, Diego Reguero-Paredes, et al.
International Journal of Molecular Sciences|January 8, 2023
Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer DiagnosisBegoña Jiménez-Rodríguez, Alfonso Alba-Bernal, Esperanza López-López, et al.
Frontiers in Oncology|November 22, 2019
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World DataTamara Díaz-Redondo, Rocio Lavado-Valenzuela, Begoña Jimenez, et al.
Pageof 12

Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
Breast Cancer Research : BCR|May 1, 2025
Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancerIñaki Comino-Méndez, Jesús Velasco-Suelto, Javier Pascual, et al.
JCO Global Oncology|March 21, 2024
Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data StudyNuria Ribelles, Javier Pascual, Laura Galvez-Carvajal, et al.
Plos One|May 29, 2015
Identification of the Lipodepsipeptide MDN-0066, a Novel Inhibitor of VHL/HIF Pathway Produced by a New Pseudomonas SpeciesBastien Cautain, Nuria de Pedro, Christian Schulz, et al.
Breast (Edinburgh, Scotland)|July 14, 2026
The landscape of clonal hematopoiesis of indeterminate potential in long-term breast cancer survivorsLaura Gálvez-Carvajal, Iñaki Comino-Méndez, Esperanza López-López, et al.
Frontiers in Oncology|December 3, 2025
Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapyAna Godoy-Ortíz, Gonzalo Lendínez-Sánchez, Manuel Zalabardo, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 3, 2024
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancerSara Santana-Hernández, Jesús Suarez-Olmos, Sonia Servitja, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2025
The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH TrialIseult M Browne, Javier Pascual, Rosalind J Cutts, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 25, 2023
Comparative study of droplet-digital PCR and absolute Q digital PCR for ctDNA detection in early-stage breast cancer patientsVictoria Sánchez-Martín, Esperanza López-López, Diego Reguero-Paredes, et al.
International Journal of Molecular Sciences|January 8, 2023
Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer DiagnosisBegoña Jiménez-Rodríguez, Alfonso Alba-Bernal, Esperanza López-López, et al.
Frontiers in Oncology|November 22, 2019
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World DataTamara Díaz-Redondo, Rocio Lavado-Valenzuela, Begoña Jimenez, et al.
Pageof 12